A61K 31/7088
Compounds having three or more nucleosides or nucleotides
A61K31/7088 (Compounds having three or more nucleosides or nucleotides) appears on 7,932 US grants and 16,981 published applications in this corpus.
Search patents in A61K- Granted patents
- 7,932
- Published applications
- 16,981
- Assignees
- 4,223
- Inventors
- 24,988
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 23 | 0 |
| 1998 | 23 | 0 |
| 1999 | 23 | 0 |
| 2000 | 23 | 0 |
| 2001 | 30 | 10 |
| 2002 | 30 | 64 |
| 2003 | 25 | 125 |
| 2004 | 26 | 118 |
| 2005 | 10 | 146 |
| 2006 | 24 | 166 |
| 2007 | 40 | 188 |
| 2008 | 29 | 247 |
| 2009 | 80 | 382 |
| 2010 | 126 | 498 |
| 2011 | 158 | 590 |
| 2012 | 260 | 600 |
| 2013 | 359 | 789 |
| 2014 | 442 | 869 |
| 2015 | 554 | 863 |
| 2016 | 547 | 937 |
| 2017 | 567 | 783 |
| 2018 | 546 | 930 |
| 2019 | 558 | 1024 |
| 2020 | 532 | 982 |
| 2021 | 542 | 1077 |
| 2022 | 581 | 1321 |
| 2023 | 465 | 1035 |
| 2024 | 477 | 1118 |
| 2025 | 481 | 1098 |
| 2026 | 344 | 1021 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 31/713Double-stranded nucleic acids or oligonucleotides3,564
- A61K 31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine2,097
- A61K 31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine805
- A61K 31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5'553
- A61K 31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine449
- A61K 31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or413
Recent patents
- Assisted loading of hydrophobic molecules into liposomes6 Oct 2026US 12,751,922 B2University of Connecticut
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Pharmaceutical composition containing anionic drug, and preparation method therefor6 Oct 2026US 12,752,010 B2Samyang Holdings Corporation
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Steroid-cationic lipid compound and use thereof8 Oct 2026US 2026/0306406 A1Cansino (Shanghai) Biological Research Co., Ltd.
- Lipid nanoparticle for delivering nucleic acid drug, and preparation method therefor and use thereof8 Oct 2026US 2026/0306419 A1Cansino (Shanghai) Biological Research Co., Ltd.
- Sik inhibitors to treat chronic kidney disease8 Oct 2026US 2026/0306463 A1The General Hospital Corporation
- Hydrogel ink, hydrogel and uses thereof8 Oct 2026US 2026/0306528 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof518US 5,550,111 ATemple University of the Commonwealth System of Higher Education · 1996
- Immunostimulatory nucleic acid molecules472US 6,207,646 B1Coley Pharmaceutical Group, Inc. · 2001
- Immunostimulatory nucleic acid molecules461US 6,239,116 B1Coley Pharmaceutical Group, Inc. · 2001
- Cationic lipids and methods for the delivery of therapeutic agents380US 8,569,256 B2Protiva Biotherapeutics, Inc. · 2013